Aripiprazole + Aripiprazole + desvenlafaxine succinate sustained release
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pharmacokinetics
Conditions
Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human
Trial Timeline
Aug 1, 2010 → Oct 1, 2010
NCT ID
NCT01188668About Aripiprazole + Aripiprazole + desvenlafaxine succinate sustained release
Aripiprazole + Aripiprazole + desvenlafaxine succinate sustained release is a approved stage product being developed by Pfizer for Pharmacokinetics. The current trial status is completed. This product is registered under clinical trial identifier NCT01188668. Target conditions include Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human.
What happened to similar drugs?
4 of 4 similar drugs in Pharmacokinetics were approved
Approved (4) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01188668 | Approved | Completed |
Competing Products
20 competing products in Pharmacokinetics